Xolair (omalizumab; Roche/Novartis) Drug Overview 2018: A Recombinant Humanized Monoclonal Antibody for the Treatment of Moderate to Severe Persistent Allergic Asthma - ResearchAndMarkets.com

DUBLIN--()--The "Drug Overview: Xolair" report has been added to ResearchAndMarkets.com's offering.

Xolair (omalizumab; Roche/Novartis) is a recombinant humanized monoclonal antibody for the treatment of moderate to severe persistent allergic asthma. The drug inhibits the binding of immunoglobulin E (IgE) antibodies to the high affinity IgE receptors present on the surface of mast cells and basophils, thereby minimizing the allergic response. Xolair is available for subcutaneous administration.

Key Topics Covered:

Product Profiles

List of Figures

Figure 1: Asthma - current and future market dynamics analysis

Figure 2: Drug assessment summary of Xolair in asthma

Figure 2: Assessment summary of key marketed and pipeline drugs for asthma

Figure 3: Asthma sales across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables

4 Table 1: Xolair drug profile

Table 2: Xolair pivotal trial data in asthma

Table 3: Xolair late-phase trial data in asthma

Table 4: Xolair sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26

For more information about this report visit https://www.researchandmarkets.com/research/jcqmzs/xolair?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Respiratory Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Respiratory Drugs